Huntington's Disease - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for Huntington's Disease including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development pipeline for Huntington's Disease

Huntington’s disease is an inherited genetic disorder, which causes the death of the brain cells. Its is a highly fatal disease causing the progressive breakdown of the nerve cells. The risk of a person developing the Huntington’s disease is about 50% due to the passing of mutated huntingtin gene from parents.  The disease could further result in pneumonia, health failure, and various other complications that could lead to the death of the patient. The prevalence of this disease across the world is about 5-10 cases per every 100,000 people. It varies on the geographical front due to various factors such as migration and ethnicity. It even spreads evenly among men and women. Furthermore, the prevalence of Huntington’s disease is high in Western Europeans, with a rate of seven people per every 100,000 people. Consequently, Technavio’s market research analysis suggests, the rising prevalence of this disease is further expected to promote the drug development for Huntington’s disease in the upcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of Huntington's Disease. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of Huntington's disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Ionis Pharmaceuticals
• Medesis Pharma
• Spark Therapeutics
• Voyager Therapeutics

Therapeutic assessment of the drug development pipeline for Huntington's Disease by route of administration

• Oral
• Intravenous
• Intrathecal
• Buccal
• Subcutaneous
• Intracerebral
• Intrastriatal

The oral route of administration (ROA) involves the application of the drug is administered directly through the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for Huntington's Disease by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, all the molecules that are currently in the drug development for pipeline for Huntington's Disease are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for Huntington's Disease?
• What are the companies that are currently involved in the development of drug development molecules for Huntington's Disease?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.